BioMimetic Therapeutics’ Augment bone graft
This article was originally published in The Gray Sheet
Executive Summary
Company files the first two of three modules of a premarket approval application with FDA for its Augment bone graft. The last module, containing clinical data, will be submitted in the fourth quarter, BioMimetic says. The firm recently reported it had closed enrollment of a 436-patient North American clinical trial comparing Augment to autograft for foot and ankle fusions (1"The Gray Sheet" Jan. 19, 2009)
You may also be interested in...
Research In Brief
Conflict-of-interest disclosure: Editorial in Oct. 15 New England Journal of Medicine outlines new disclosure requirements for study authors, which will be adopted by all members of the International Committee of Medical Journal Editors. Under the new 1disclosure form, authors are asked to divulge four types of information: associations with commercial entities that provided support for the work reported in the submitted manuscript; associations with entities that could be viewed as having an interest in the general area of the submitted manuscript; similar financial associations involving spouses or children under 18 years old; and non-financial associations that may be relevant to the submitted manuscript. Because the new disclosure form has only been "use tested" by ICMJE member journals and may need adjustments, Oct. 15 to April 10, 2010, will be considered a beta-testing period, the editorial says
Research In Brief
Test improves DES outcomes: Routine measurement of fractional flow reserve (FFR) - the ratio of maximal blood flow in a stenotic artery to normal maximal flow - with St. Jude's PressureWire Certus guidewire-mounted sensor improves outcomes of drug-eluting stent implants in patients with multivessel coronary artery disease, according to results of the FAME trial published in the Jan. 15 New England Journal of Medicine. The 20-center trial randomized 1,005 patients with multivessel disease to undergo implantation of drug-eluting stents guided by angiography and FFR or drug-eluting stent implantation guided by angiography alone. The overall composite adverse event rates were 18.3% in the angiography-alone group and 13.2% in the FFR group. Adverse events included death, non-fatal myocardial infarction and repeat revascularization. The trial also showed that including FFR in the procedure saved money and only added one minute to the average procedure time (71 minutes versus 70 minutes). The average procedure cost was $6,007 in the angiography-alone group compared to $5,332 for the FFR group, partly because FFR measurement led to the implant of fewer stents. The FFR group received an average of 1.9 stents per patient compared to 2.7 for the angiography-alone group, even though patients in the FFR group had an average of 2.8 coronary lesions compared to 2.7 for the angiography-alone group. The study was sponsored by Medtronic, Friends of the Heart Foundation and St. Jude Medical/Radi Medical Systems
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.